Nanoviricides (NNVC) Non-Current Assets (2011 - 2026)
Nanoviricides (NNVC) posted Non-Current Assets of $6.8 million for Q1 2026, down 1.86% sequentially from $7.0 million in Q4 2025, and down 6.35% YoY from $7.3 million in Q1 2025.
Nanoviricides (NNVC) Non-Current Assets (2011 - 2026) Analysis & Trends
Nanoviricides has reported Non-Current Assets for 16 years, with the latest figure at $6.8 million in Q1 2026.
- Quarterly Non-Current Assets fell 6.35% year-over-year to $6.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.1 million (down 7.53% YoY) and the FY2025 annual result came in at $7.2 million, down 8.9% from the prior year.
- Non-Current Assets fell to $6.8 million in Q1 2026 per NNVC's latest filing, from $7.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $9.2 million in Q1 2022 and troughed at $6.8 million in Q1 2026.
- A 5-year average of $8.0 million and a median of $7.9 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets slipped 3.49% in 2022, then retreated 8.9% in 2025.
- Over 5 years, Non-Current Assets stood at $8.8 million in 2022, then declined by 7.94% to $8.1 million in 2023, then slipped by 7.24% to $7.5 million in 2024, then dropped by 7.04% to $7.0 million in 2025, then declined by 1.86% to $6.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $6.8 million, $7.0 million, and $7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Nanoviricides | 28.74 Mn | 25.53 Mn | - | 6.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.84 Mn |
| Dec 31, 2025 | 6.97 Mn |
| Sep 30, 2025 | 7.10 Mn |
| Jun 30, 2025 | 7.15 Mn |
| Mar 31, 2025 | 7.30 Mn |
| Dec 31, 2024 | 7.50 Mn |
| Sep 30, 2024 | 7.70 Mn |
| Jun 30, 2024 | 7.85 Mn |
| Mar 31, 2024 | 7.95 Mn |
| Dec 31, 2023 | 8.08 Mn |
| Sep 30, 2023 | 8.27 Mn |
| Jun 30, 2023 | 8.45 Mn |
| Mar 31, 2023 | 8.65 Mn |
| Dec 31, 2022 | 8.78 Mn |
| Sep 30, 2022 | 8.93 Mn |
| Jun 30, 2022 | 9.08 Mn |
| Mar 31, 2022 | 9.20 Mn |
| Dec 31, 2021 | 9.29 Mn |
| Sep 30, 2021 | 9.29 Mn |
| Jun 30, 2021 | 9.44 Mn |